Venture Capital Investment | Plutus Investment Group
About Us
A team of industry experts with a successful investment experience
Our Philosophy
Investing in Tomorrow’s Champions
Founded in 2021 by a seasoned group of entrepreneurs, investors and industry veterans, Plutus Investment Group is a family office that focuses on backing startups in Europe and the USA.
We’re looking for leaders with a drive and a strong vision. While we only invest in a handful of companies a year, it means we can provide the time, the energy and the capital for those companies to succeed and become a game changers
About
Our Management Team
Member Name
Member Position
Member Description
Our team and board combined investment experience exceeds 180 years
MOHAMMED JAMAL
Founder, Chief Executive Officer & Chairman
Bio
Mr Jamal has over 22 years of experience in structuring, placement, trading, private equity and liquid Investing. Mr Jamal started his career at Morgan Stanley in the structured credit team in 2003. In 2009 Mr Jamal moved to Resource America a $15Bn credit fund to lead their business in Europe.
In 2012 Mr Jamal founded Molton Street Capital a London based CLO, CDO and ABS trading company that traded over $3Bn.
In 2016 Mr Jamal co-founded Forepont Capital Group, a leading life science Venture Capital fund with office in London, New York and Paris
Mr Jamal invested in more than 40 companies since 2012 besides helping them build from seed stage and made multiple successful exits.
Mr Jamal holds a Masters degree in Applied Mathematics and Computer Sciences from Ecole Centrale Paris (top French “ Grande Ecole” ) and an advanced degree (DEA) in Finance and Economics from La Sorbonne University in Paris.
PRASHANT MORI
Chief Operating Officer & Chief Scientist
Bio
An Entrepreneur, Drug Discovery & Diagnostic Research Scientist with 19 years of proficiency in biopharma and drug R&D, on numerous drug targets including New Chemical Entity & New Biological Entity at various stages. Thus, possess a comprehensive understanding of various processes involved in drug research, discovery, development, leading to pre-clinical stages. An avid Artificial Intelligent proponent, he is an expert in Molecular Biology, Biochemistry and Biophysics. Worked with TCR based Immunotherapy when the technology was in infant stage at Avidex (Now Immunocore & Adapimmune ) and other programs in laboratory which is now successfully marketed drugs in the market (Bimekizumab – UCB Pharma). Discovered novel way to decipher PPI for designing drug like molecules for TNF modulation to integrate the idea in drug development program which was partnered with Sanofi for multi million pounds and profit-sharing deal, on achievable milestones. He has lead teams, to set-up and manage small businesses, communal laboratories, besides supporting and expanding family’s Salt, Mining & Commodities businesses internationally. Multifaceted persona with culmination of science and business, Prashant brings on board lateral thinking to solve technical problems and help expand Biopharma, Diagnostics & AI based businesses.
TIM CHEN
Investment Partner & Board Member
Bio
20+ years in business. Built and led operations across Europe and Asia. From strategy to execution, from factory floor to boardroom. Industrial, M&A-hands-on, outcome-driven.
Now shifting focus-into investment. Backing what matters. Leading Swiss Lucida Family Office and partnering with Plutus Investment UK to support ventures with depth: life science, security, and deep tech. Strong IP. Real-world use. Global potential.
Not just capital. Strategic support. Operational guidance.
Trusted network. Smart capital with skin in the game.
What I bring: survival instinct from the operator’s side.
Pattern recognition from the investor’s lens. A global network that opens doors. A partner who knows what it takes-not just to start, but to finish well.
If you’re building with purpose and looking for more thar funding-let’s talk.
Member Name
Member Position
Member Description
FAHD LAHRACH
Chief of Staff
Bio
Fahd is a highly motivated and detail-oriented professional with a strong academic foundation and practical experience at the intersection of business law and real estate. He holds a Master’s Degree in Business Law, complemented by a certificate in M&A and Corporate Development Strategies from The Wharton School, University of Pennsylvania. This combination has strengthened his ability to approach legal, financial, and strategic challenges with a comprehensive and results-oriented perspective.
With solid experience in navigating complex legal, fiscal, and tax matters, Fahd brings a unique blend of analytical rigor and creative problem-solving to his work. His background enables him to evaluate risks, structure transactions, and support decision-making processes with clarity and precision.
Throughout his career, he has demonstrated a strong capacity to adapt quickly to fast-paced environments, collaborate effectively with multidisciplinary teams, and consistently deliver high-quality outcomes. His passion for real estate, paired with his legal and strategic expertise, allows him to contribute meaningfully to value-driven projects and high-impact initiatives.
Recognized for his professionalism, commitment, and strategic mindset, Fahd is continually seeking new challenges and opportunities to grow, contribute, and create lasting impact.
The Geniuses Behind Our Work
Board Members
We have an outstanding Board Of Directors with an extended expertise in key industries
MOHAMMED JAMAL
Founder, Chief Executive Officer & Chairman (London)
Bio
Mr Jamal has over 22 years of experience in structuring, placement, trading, private equity and liquid Investing.
Mr Jamal started his career at Morgan Stanley in the structured credit team in 2003. In 2009 Mr Jamal moved to Resource America a $15Bn credit fund to lead their business in Europe.
In 2012 Mr Jamal founded Molton Street Capital a London based CLO, CDO and ABS trading company that traded over $3Bn.
In 2016 Mr Jamal co-founded Forepont Capital Group, a leading life science Venture Capital fund with office in London, New York and Paris
Mr Jamal invested in more than 40 companies besides helping them build from nascent stage since 2012 and made multiple successful exits.
Mr Jamal holds a Masters degree in Applied Mathematics and Computer Sciences from Ecole Centrale Paris (top French “ Grande Ecole” ) and an advanced degree (DEA) in Finance and Economics from La Sorbonne University in Paris.
JAMAL BUTT, FRPharmS
Venture Partner – Bio-Pharma & Med. Devices (London)
Bio
Jamal is a seasoned healthcare leader with over 25 years of experience in healthcare service transformation, digital technology innovation, life science start ups and commercial operations. He is currently the Entrepreneur in Residence at Cambridge University, where he supports and promotes the commercialisation of life changing innovation via spin-out companies. He was previously the CEO of MedAdvisor UK, one of the world’s largest SaaS platforms for medication management and digital adherence programmes.
He also contributes to the healthcare sector as a Fellow of the Royal Pharmaceutical Society, a Non-Executive Director at Croydon Health Services NHS Trust, and a Chair of the Croydon Health Charity Committee. He holds several Non Executive Director positions for digital start-ups from Cambridge University.
He was previously on the pharmacy boards of both Boots UK and LloydsPharmacy UK, where he led the operations and service innovation teams, including introducing out-sourced out patient dispensaries into the UK. He holds a Bachelor of Pharmacy from UCL and a certificate in Digital Disruption Models from Cambridge Judge Business School. He also studied Finance and Management at Oxford University Said Business School, and AI transformation at Imperial Business School. He is a strong advocate for integrated and patient-centric healthcare solutions that improve outcomes and efficiency.
Member Name
Member Position
Member Description
Dr. RITA DOBMEYER
Science Advisor & Venture Partner (Frankfurt)
Bio
Dr. Rita Dobmeyer has spent more than 10 years in science and academic research and is the founder of several consulting, service and clinical development companies in the area of biotech and medical science. Dr. Rita Dobmeyer is an experienced, serial entrepreneur and highly qualified scientific expert in immunology, infectious diseases and strategic clinical development.
In her scientific career, she has graduated with a PhD in immunology and infectious diseases at the German Cancer Research Centre in Heidelberg, Germany in the Department of the later Nobel prize winner Prof Harald zur Hausen, Heidelberg, Germany. She was a project lead in the European Union funded HIV BioMed Research Group of Prof Luc Montagnier, Paris, France who shared the Nobel prize with Harald zur Hausen in 2008. Rita is a presenter and chairman at prestigious international conferences; she is the author of numerous book articles publications in Peer Reviewed Scientific journals.
In her business career, she assisted biotech clients using her strong, long term relationship to global key opinion leaders and investors community to secure funding for early and late stage clinical development programs. She contributed to the successful execution of complex clinical development plans in the area of infectious achieving marketing authorizations in US and EU.
RADOUANE OUDRHIRI PhD
Head of Information Technology & Artificial Intelligence (London)
Bio
Dr. Radouane has an extensive experience in leading world-class software and data-intensive system developments in different industries from Telecom to Healthcare, Nuclear, Automotive, Financials. Expert in IT and software architecture, design, quality engineering and sits as Scientific or Technology advisor on the board of multiple technology companies. He is involved in starting the organisations from scratch, building, growing, and improving the value and performance of from seed stage to large corporates.
Lecturer at various European universities and Engineering schools, on Innovation, Information Systems and software engineering he is evaluator with the European Commission information technology directorate. A regular conference speaker on Software Quality Engineering, Six Sigma and DFSS for IT and Software development he possesses proficiency in computer systems validation and compliance in pharmaceuticals and related life-sciences.
A Fellow of the Royal Statistical Society (RSS) and member of the ISO Technical Committee (TC69: Applications of Statistical methods) Radouane has co-authored the Lean & Six Sigma Standard (ISO 18404) as well as the new standard under development (Design for Six Sigma) besides being a part of the newly formed international Group on Big Data (nominated by BSI as the UK representative/expert), he was recently nominated as the Convenor of the working group on Design of Experiments.
Dr. SAIMA AJAZ
Life Science Advisor & Venture Partner (London)
Bio
Dr. Ajaz is a highly accomplished hepatologist and metabolic health specialist with over 20 years of clinical
experience, with a particular focus on Metabolic-Associated Steatohepatitis Liver Disease (MASLD), fatty
liver disease, and chronic metabolic disorders. Following her clinical training, she completed an MPhil in
Biochemistry and Molecular Biology, and a PhD in Diabetes, Endocrinology, and Metabolism from King’s
College London (KCL) in 2016. Dr. Ajaz has been at the forefront of clinical research and service
development for MASLD at the Institute of Liver Studies, King’s College Hospital, where she leads patient-
centred initiatives and research into non-invasive biomarkers for liver fibrosis and cancer, including holding
patents for novel biomarker panels developed at KCH. Her scientific focus has been on mitochondrial
dysfunction and bioenergetics as central drivers of chronic disease and regenerative pathways, linking
metabolic stress to liver injury, multi-organ health, and opportunities for novel therapeutic interventions.
She is the only certified Lifestyle Medicine physician working within a UK hepatology unit, bringing a
unique, preventive, and patient-focused approach to liver care. Her innovative leadership includes founding
LIVFIT, the UK’s first interactive MASLD patient support group, and establishing the first UK MASLD
Advocacy Academy, both of which empower patients to engage actively in their care pathways.
Internationally recognised for her contributions, Dr. Ajaz integrates lifestyle, nutrition, regenerative
medicine, and personalised approaches into the management of chronic liver and metabolic diseases. She
continues to bridge clinical innovation with translational research, ensuring that advances in bioenergetics,
mitochondrial biology, and regenerative therapies are embedded into patient-centred care model.